Inhibition of proteasome deubiquitinase activity: A strategy to overcome resistance to conventional proteasome inhibitors?

Drug Resistance Updates

Volumn 21-22, Issue , 2015, Pages 20-29

  Selvaraju, Karthik ^a   Mazurkiewicz, Magdalena ^b   Wang, Xin ^a   Gullbo, Joachim ^c   Linder, Stig ^a,b   D'Arcy, Pádraig ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Cancer therapeutics; Deubiquitinase; DUB; Proteasome; Small molecule inhibitors; , Unsaturated ketones

Indexed keywords

BORTEZOMIB; DEUBIQUITINASE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; NEOPLASM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HUMAN; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEASOME INHIBITORS; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84941171799     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.06.001     Document Type: Article

References (112)

1. G. Aldini, I. Dalle-Donne, R. Colombo, R. Maffei Facino, A. Milzani, and M. Carini Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction ChemMedChem 1 2006 1045 1058
2. E. Aleo, C.J. Henderson, A. Fontanini, B. Solazzo, and C. Brancolini Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis Cancer Res. 66 2006 9235 9244
3. X.I. Ambroggio, D.C. Rees, and R.J. Deshaies JAMM: a metalloprotease-like zinc site in the proteasome and signalosome PLoS Biol. 2 2004 E2
4. A.Y. Amerik, and M. Hochstrasser Mechanism and function of deubiquitinating enzymes Biochim. Biophys. Acta 1695 2004 189 207
5. R.K. Anchoori, S.R. Khan, T. Sueblinvong, A. Felthauser, Y. Iizuka, R. Gavioli, F. Destro, R. Isaksson Vogel, S. Peng, R.B. Roden, and M. Bazzaro Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells PLoS One 6 2011 e23888
6. Y.G. Assaraf Molecular basis of antifolate resistance Cancer Metastasis Rev. 26 2007 153 181
7. M. Bochtler, L. Ditzel, M. Groll, C. Hartmann, and R. Huber The proteasome Annual Rev. Biophys. Biomol.Struct. 28 1999 295 317
8. S. Bohn, F. Beck, E. Sakata, T. Walzthoeni, M. Beck, R. Aebersold, F. Forster, W. Baumeister, and S. Nickell Structure of the 26S proteasome from Schizosaccharomyces pombe at subnanometer resolution Proc. Natl. Acad. Sci. U. S. A. 107 2010 20992 20997
9. A. Borodovsky, B.M. Kessler, R. Casagrande, H.S. Overkleeft, K.D. Wilkinson, and H.L. Ploegh A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14 EMBO J. 20 2001 5187 5196
10. S. Brnjic, M. Mazurkiewicz, M. Fryknas, C. Sun, X. Zhang, R. Larsson, P. D'Arcy, and S. Linder Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress Antioxid. Redox Signal. 21 2014 2271 2285
11. S. Byun, S.Y. Lee, J. Lee, C.H. Jeong, L. Farrand, S. Lim, K. Reddy, J.Y. Kim, M.H. Lee, H.J. Lee, A.M. Bode, K. Won Lee, and Z. Dong USP8 is a novel target for overcoming gefitinib resistance in lung cancer Clin. Cancer Res. 19 2013 3894 3904
12. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T.H. Chao, S.T. Neuteboom, P. Richardson, M.A. Palladino, and K.C. Anderson A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 8 2005 407 419
13. D. Chauhan, Z. Tian, B. Nicholson, K.G. Kumar, B. Zhou, R. Carrasco, J.L. McDermott, C.A. Leach, M. Fulcinniti, M.P. Kodrasov, J. Weinstock, W.D. Kingsbury, T. Hideshima, P.K. Shah, S. Minvielle, M. Altun, B.M. Kessler, R. Orlowski, P. Richardson, N. Munshi, and K.C. Anderson A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance Cancer Cell 22 2012 345 358
14. P.C. Chen, L.N. Qin, X.M. Li, B.J. Walters, J.A. Wilson, L. Mei, and S.M. Wilson The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions J. Neurosci.: Off. J. Soc. Neurosci. 29 2009 10909 10919
15. T.A. Chernova, K.D. Allen, L.M. Wesoloski, J.R. Shanks, Y.O. Chernoff, and K.D. Wilkinson Pleiotropic effects of Ubp6 loss on drug sensitivities and yeast prion are due to depletion of the free ubiquitin pool J. Biol. Chem. 278 2003 52102 52115
16. S.G. Codreanu, J.C. Ullery, J. Zhu, K.A. Tallman, W.N. Beavers, N.A. Porter, L.J. Marnett, B. Zhang, and D.C. Liebler Alkylation damage by lipid electrophiles targets functional protein systems Mol. Cell. Proteomics: MCP 13 2014 849 859
17. K. Coughlin, R. Anchoori, Y. Iizuka, J. Meints, L. MacNeill, R.I. Vogel, R.Z. Orlowski, M.K. Lee, R.B. Roden, and M. Bazzaro Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses Clin. Cancer Res. 20 2014 3174 3186
18. O. Coux, K. Tanaka, and A.L. Goldberg Structure and functions of the 20S and 26S proteasomes Annu. Rev. Biochem. 65 1996 801 847
19. P. D'Arcy, S. Brnjic, M.H. Olofsson, M. Fryknas, K. Lindsten, M. De Cesare, P. Perego, B. Sadeghi, M. Hassan, R. Larsson, and S. Linder Inhibition of proteasome deubiquitinating activity as a new cancer therapy Nat. Med. 17 2011 1636 1640
20. L.H. de Wilt, G. Jansen, Y.G. Assaraf, J. van Meerloo, J. Cloos, A.D. Schimmer, E.T. Chan, C.J. Kirk, G.J. Peters, and F.A. Kruyt Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer Biochem. Pharmacol. 83 2012 207 217
21. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, M.N. Ho, J. Jiang, G.J. Laidig, E.R. Lewis, F. Parlati, K.D. Shenk, M.S. Smyth, C.M. Sun, M.K. Vallone, T.M. Woo, C.J. Molineaux, and M.K. Bennett Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res. 67 2007 6383 6391
22. Q. Deveraux, V. Ustrell, C. Pickart, and M. Rechsteiner A 26 S protease subunit that binds ubiquitin conjugates J. Biol. Chem. 269 1994 7059 7061
23. D. Finley Recognition and processing of ubiquitin-protein conjugates by the proteasome Annu. Rev. Biochem. 78 2009 477 513
24. N. Fortelny, J.H. Cox, R. Kappelhoff, A.E. Starr, P.F. Lange, P. Pavlidis, and C.M. Overall Network analyses reveal pervasive functional regulation between proteases in the human protease web PLoS Biol. 12 2014 e1001869
25. J.M. Fraile, V. Quesada, D. Rodriguez, J.M. Freije, and C. Lopez-Otin Deubiquitinases in cancer: new functions and therapeutic options Oncogene 31 2012 2373 2388
26. N.E. Franke, D. Niewerth, Y.G. Assaraf, J. van Meerloo, K. Vojtekova, C.H. van Zantwijk, S. Zweegman, E.T. Chan, C.J. Kirk, D.P. Geerke, A.D. Schimmer, G.J. Kaspers, G. Jansen, and J. Cloos Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells Leukemia 4 2011 757 768
27. M. Gallery, J.L. Blank, Y. Lin, J.A. Gutierrez, J.C. Pulido, D. Rappoli, S. Badola, M. Rolfe, and K.J. Macbeth The JAMM motif of human deubiquitinase Poh1 is essential for cell viability Mol. Cancer Ther. 6 2007 262 268
28. M.H. Glickman, D.M. Rubin, O. Coux, I. Wefes, G. Pfeifer, Z. Cjeka, W. Baumeister, V.A. Fried, and D. Finley A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3 Cell 94 1998 615 623
29. A.L. Goldberg Protein degradation and protection against misfolded or damaged proteins Nature 426 2003 895 899
30. A.L. Goldberg Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy Biochem. Soc. Trans. 35 2007 12 17
31. N. Gonen, and Y.G. Assaraf Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 15 2012 183 210
32. M. Groll, L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H.D. Bartunik, and R. Huber Structure of 20S proteasome from yeast at 2.4 A resolution Nature 386 1997 463 471
33. J. Hagenbuchner, M.J. Ausserlechner, V. Porto, R. David, B. Meister, M. Bodner, A. Villunger, K. Geiger, and P. Obexer The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression J. Biol. Chem. 285 2010 6904 6912
34. J. Hamazaki, S. Iemura, T. Natsume, H. Yashiroda, K. Tanaka, and S. Murata A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes EMBO J. 25 2006 4524 4536
35. J. Hanna, N.A. Hathaway, Y. Tone, B. Crosas, S. Elsasser, D.S. Kirkpatrick, D.S. Leggett, S.P. Gygi, R.W. King, and D. Finley Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation Cell 127 2006 99 111
36. T.M. Herndon, A. Deisseroth, E. Kaminskas, R.C. Kane, K.M. Koti, M.D. Rothmann, B. Habtemariam, J. Bullock, J.D. Bray, J. Hawes, T.R. Palmby, J. Jee, W. Adams, H. Mahayni, J. Brown, A. Dorantes, R. Sridhara, A.T. Farrell, and R. Pazdur U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma Clin. Cancer Res. 19 2013 4559 4563
37. A. Hershko, and A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425 479
38. A. Hershko, H. Heller, S. Elias, and A. Ciechanover Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown J. Biol. Chem. 258 1983 8206 8214
39. J.H. Hooijberg, H.J. Broxterman, M. Kool, Y.G. Assaraf, G.J. Peters, P. Noordhuis, R.J. Scheper, P. Borst, H.M. Pinedo, and G. Jansen Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 Cancer Res. 59 1999 2532 2535
40. M. Hu, P. Li, L. Song, P.D. Jeffrey, T.A. Chenova, K.D. Wilkinson, R.E. Cohen, and Y. Shi Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14 EMBO J. 24 2005 3747 3756
41. K. Husnjak, S. Elsasser, N. Zhang, X. Chen, L. Randles, Y. Shi, K. Hofmann, K.J. Walters, D. Finley, and I. Dikic Proteasome subunit Rpn13 is a novel ubiquitin receptor Nature 453 2008 481 488
42. O.A. Issaenko, and A.Y. Amerik Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes Cell Cycle 11 2012 1804 1817
43. A.D. Jacobson, N.Y. Zhang, P. Xu, K.J. Han, S. Noone, J. Peng, and C.W. Liu The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 s proteasome J. Biol. Chem. 284 2009 35485 35494
44. N. Johnson-Farley, J. Veliz, S. Bhagavathi, and J.R. Bertino ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells Leuk. Lymphoma 2015 1 7
45. A.J. Kale, and B.S. Moore Molecular mechanisms of acquired proteasome inhibitor resistance J. Med. Chem. 55 2012 10317 10327
46. D. Komander, M.J. Clague, and S. Urbe Breaking the chains: structure and function of the deubiquitinases Nat. Rev. Mol. Cell Biol. 10 2009 550 563
47. E. Koulich, X. Li, and G.N. DeMartino Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome Mol. Biol. Cell 19 2008 1072 1082
48. Y. Kulathu, and D. Komander Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages Nat. Rev. Mol. Cell Biol. 13 2012 508 523
49. S. Kumar, and S.V. Rajkumar Many facets of bortezomib resistance/susceptibility Blood 112 2008 2177 2178
50. N. Kunami, H. Katsuya, R. Nogami, K. Ishitsuka, and K. Tamura Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma Anticancer Res. 34 2014 5287 5294
51. Y.A. Lam, W. Xu, G.N. DeMartino, and R.E. Cohen Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome Nature 385 1997 737 740
52. J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, M.J. Wrobel, J. Lerner, J.P. Brunet, A. Subramanian, K.N. Ross, M. Reich, H. Hieronymus, G. Wei, S.A. Armstrong, S.J. Haggarty, P.A. Clemons, R. Wei, S.A. Carr, E.S. Lander, and T.R. Golub The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science (New York, N.Y.) 313 2006 1929 1935
53. G.C. Lander, E. Estrin, M.E. Matyskiela, C. Bashore, E. Nogales, and A. Martin Complete subunit architecture of the proteasome regulatory particle Nature 482 2012 186 191
54. B.H. Lee, M.J. Lee, S. Park, D.C. Oh, S. Elsasser, P.C. Chen, C. Gartner, N. Dimova, J. Hanna, S.P. Gygi, S.M. Wilson, R.W. King, and D. Finley Enhancement of proteasome activity by a small-molecule inhibitor of USP14 Nature 467 2010 179 184
55. M.J. Lee, B.H. Lee, J. Hanna, R.W. King, and D. Finley Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes Mol. Cell. Proteomics: MCP 10 2011 (R110.003871)
56. M.J. Lee, B.H. Lee, J. Hanna, R.W. King, and D. Finley Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes Mol. Cell. Proteomics 10 2011 R110003871
57. D.S. Leggett, J. Hanna, A. Borodovsky, B. Crosas, M. Schmidt, R.T. Baker, T. Walz, H. Ploegh, and D. Finley Multiple associated proteins regulate proteasome structure and function Mol. Cell 10 2002 495 507
58. T. Li, N.I. Naqvi, H. Yang, and T.S. Teo Identification of a 26S proteasome-associated UCH in fission yeast Biochem. Biophys. Res. Commun. 272 2000 270 275
59. Y.D. Livney, and Y.G. Assaraf Rationally designed nanovehicles to overcome cancer chemoresistance Adv. Drug Deliv. Rev. 65 2013 1716 1730
60. J. Lowe, D. Stock, B. Jap, P. Zwickl, W. Baumeister, and R. Huber Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution Science (New York, N.Y.) 268 1995 533 539
61. S. Lu, J. Yang, X. Song, S. Gong, H. Zhou, L. Guo, N. Song, X. Bao, P. Chen, and J. Wang Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line J. Pharmacol. Exp. Ther. 326 2008 423 431
62. L. Ma, and A. Diao Marizomib, a potent second generation proteasome inhibitor from natural origin Anti-cancer Agents Med. Chem. 2014
63. V. Maytal-Kivity, N. Reis, K. Hofmann, and M.H. Glickman MPN+, a putative catalytic motif found in a subset of MPN domain proteins from eukaryotes and prokaryotes, is critical for Rpn11 function BMC Biochem. 3 2002 28
64. S. Meister, U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, H.M. Jack, and R.E. Voll Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Res. 67 2007 1783 1792
65. V. Menendez-Benito, L.G. Verhoef, M.G. Masucci, and N.P. Dantuma Endoplasmic reticulum stress compromises the ubiquitin-proteasome system Hum. Mol. Genet. 14 2005 2787 2799
66. H. Minderman, Y. Zhou, K.L. O'Loughlin, and M.R. Baer Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status Cancer Chemother. Pharmacol. 60 2007 245 255
67. C.S. Mitsiades, T. Hideshima, D. Chauhan, D.W. McMillin, S. Klippel, J.P. Laubach, N.C. Munshi, K.C. Anderson, and P.G. Richardson Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib Semin. Hematol. 46 2009 166 175
68. B. Nicholson, C.A. Leach, S.J. Goldenberg, D.M. Francis, M.P. Kodrasov, X. Tian, J. Shanks, D.E. Sterner, A. Bernal, M.R. Mattern, K.D. Wilkinson, and T.R. Butt Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities Protein Sci.: Publ. Protein Soc. 17 2008 1035 1043
69. D. Niewerth, G. Jansen, Y.G. Assaraf, S. Zweegman, G.J. Kaspers, and J. Cloos Molecular basis of resistance to proteasome inhibitors in hematological malignancies Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 18 2015 18 35
70. D. Niewerth, G. Jansen, L.F. Riethoff, J. van Meerloo, A.J. Kale, B.S. Moore, Y.G. Assaraf, J.L. Anderl, S. Zweegman, G.J. Kaspers, and J. Cloos Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib) Mol. Pharmacol. 86 2014 12 19
71. D. Niewerth, G.J. Kaspers, Y.G. Assaraf, J. van Meerloo, C.J. Kirk, J. Anderl, J.L. Blank, P.M. van de Ven, S. Zweegman, G. Jansen, and J. Cloos Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines J. Hematol. Oncol. 7 2014 7
72. S.M. Nijman, M.P. Luna-Vargas, A. Velds, T.R. Brummelkamp, A.M. Dirac, T.K. Sixma, and R. Bernards A genomic and functional inventory of deubiquitinating enzymes Cell 123 2005 773 786
73. A. Obaidat, J. Weiss, B. Wahlgren, R.R. Manam, V.R. Macherla, K. McArthur, T.H. Chao, M.A. Palladino, G.K. Lloyd, B.C. Potts, S.J. Enna, S.T. Neuteboom, and B. Hagenbuch Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs J. Pharmacol. Exp. Ther. 337 2011 479 486
74. R. Oerlemans, N.E. Franke, Y.G. Assaraf, J. Cloos, I. van Zantwijk, C.R. Berkers, G.L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, J.W. van der Heijden, B. Ylstra, G.J. Peters, G.L. Kaspers, B.A. Dijkmans, R.J. Scheper, and G. Jansen Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood 112 2008 2489 2499
75. L. Paoluzzi, M. Gonen, J.R. Gardner, J. Mastrella, D. Yang, J. Holmlund, M. Sorensen, L. Leopold, K. Manova, G. Marcucci, M.L. Heaney, and O.A. O'Connor Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma Blood 111 2008 5350 5358
76. A. Peth, H.C. Besche, and A.L. Goldberg Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening Mol. Cell 36 2009 794 804
77. A. Peth, N. Kukushkin, M. Bosse, and A.L. Goldberg Ubiquitinated proteins activate the proteasomal ATPases by binding to Usp14 or Uch37 homologs J. Biol. Chem. 288 2013 7781 7790
78. C.M. Pickart, and M.J. Eddins Ubiquitin: structures, functions, mechanisms Biochim. Biophys. Acta 1695 2004 55 72
79. J. Piotrowski, R. Beal, L. Hoffman, K.D. Wilkinson, R.E. Cohen, and C.M. Pickart Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths J. Biol. Chem. 272 1997 23712 23721
80. G. Puhler, S. Weinkauf, L. Bachmann, S. Muller, A. Engel, R. Hegerl, and W. Baumeister Subunit stoichiometry and three-dimensional arrangement in proteasomes from Thermoplasma acidophilum EMBO J. 11 1992 1607 1616
81. X.B. Qiu, S.Y. Ouyang, C.J. Li, S. Miao, L. Wang, and A.L. Goldberg hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37 EMBO J. 25 2006 5742 5753
82. S.N. Reuland, N.B. Goldstein, K.A. Partyka, S. Smith, Y. Luo, M. Fujita, R. Gonzalez, K. Lewis, D.A. Norris, and Y.G. Shellman ABT-737 synergizes with Bortezomib to kill melanoma cells Biol.Open 1 2012 92 100
83. M. Ri, S. Iida, T. Nakashima, H. Miyazaki, F. Mori, A. Ito, A. Inagaki, S. Kusumoto, T. Ishida, H. Komatsu, Y. Shiotsu, and R. Ueda Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress Leukemia 24 2010 1506 1512
84. P.G. Richardson, and K.C. Anderson Bortezomib: a novel therapy approved for multiple myeloma Clin. Adv. Hematol. Oncol. 1 2003 596 600
85. T. Rinaldi, C. Ricci, D. Porro, M. Bolotin-Fukuhara, and L. Frontali A mutation in a novel yeast proteasomal gene, RPN11/MPR1, produces a cell cycle arrest, overreplication of nuclear and mitochondrial DNA, and an altered mitochondrial morphology Mol. Biol. Cell 9 1998 2917 2931
86. H. Rumpold, C. Salvador, A.M. Wolf, H. Tilg, G. Gastl, and D. Wolf Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors Biochem. Biophys. Res. Commun. 361 2007 549 554
87. S. Shinji, Z. Naito, S. Ishiwata, T. Ishiwata, N. Tanaka, K. Furukawa, H. Suzuki, T. Seya, A. Matsuda, M. Katsuta, and T. Tajiri Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases Oncol. Rep. 15 2006 539 543
88. A.V. Singh, M.A. Palladino, G.K. Lloyd, B.C. Potts, D. Chauhan, and K.C. Anderson Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model Br. J. Haematol. 149 2010 550 559
89. A.J. Smith, H. Dai, C. Correia, R. Takahashi, S.H. Lee, I. Schmitz, and S.H. Kaufmann Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells J. Biol. Chem. 286 2011 17682 17692
90. E. Suzuki, S. Demo, E. Deu, J. Keats, S. Arastu-Kapur, P.L. Bergsagel, M.K. Bennett, and C.J. Kirk Molecular mechanisms of bortezomib resistant adenocarcinoma cells PLoS One 6 2011 e27996
91. M. Suzuki, M. Mori, T. Niwa, R. Hitrata, K. Furuta, T. Ishikawa, and R. Noyori Chemical implications for antitumor and antiviral prostaglandins: reaction of D7-prostaglandin A1 and prostaglandin A1 methyl esters with thiols J. Am. Chem. Soc. 119 1997 2376 2385
92. S.G. Tajc, B.S. Tolbert, R. Basavappa, and B.L. Miller Direct determination of thiol pKa by isothermal titration microcalorimetry J. Am. Chem. Soc. 126 2004 10508 10509
93. K. Tanaka, L. Waxman, and A.L. Goldberg ATP serves two distinct roles in protein degradation in reticulocytes, one requiring and one independent of ubiquitin J. Cell Biol. 96 1983 1580 1585
94. K.D. Tew, A. Monks, L. Barone, D. Rosser, G. Akerman, J.A. Montali, J.B. Wheatley, and D.E. Schmidt Jr. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program Mol. Pharmacol. 50 1996 149 159
95. Z. Tian, P. D'Arcy, X. Wang, A. Ray, Y.T. Tai, Y. Hu, R.D. Carrasco, P. Richardson, S. Linder, D. Chauhan, and K.C. Anderson A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance Blood 125 2013 706 716
96. R.J. Tomko Jr., M. Funakoshi, K. Schneider, J. Wang, and M. Hochstrasser Heterohexameric ring arrangement of the eukaryotic proteasomal ATPases: implications for proteasome structure and assembly Mol. Cell 38 2010 393 403
97. D.M. Townsend, and K.D. Tew The role of glutathione-S-transferase in anti-cancer drug resistance Oncogene 22 2003 7369 7375
98. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, N. Yasuoka, and T. Tsukihara The structure of the mammalian 20S proteasome at 2.75 A resolution Structure (London, England: 1993) 10 2002 609 618
99. S.E. Verbrugge, Y.G. Assaraf, B.A. Dijkmans, G.L. Scheffer, M. Al, D. den Uyl, R. Oerlemans, E.T. Chan, C.J. Kirk, G.J. Peters, J.W. van der Heijden, T.D. de Gruijl, R.J. Scheper, and G. Jansen Inactivating PSMB5 mutations and P-glycoprotein (MDR1/ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients J. Pharmacol. Exp.Ther. 341 2012 174 182
100. R. Verma, L. Aravind, R. Oania, W.H. McDonald, J.R. Yates 3rd, E.V. Koonin, and R.J. Deshaies Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome Science (New York, N.Y.) 298 2002 611 615
101. D. Voges, P. Zwickl, and W. Baumeister The 26S proteasome: a molecular machine designed for controlled proteolysis Annu. Rev. Biochem. 68 1999 1015 1068
102. B.J. Walters, S.L. Campbell, P.C. Chen, A.P. Taylor, D.G. Schroeder, L.E. Dobrunz, K. Artavanis-Tsakonas, H.L. Ploegh, J.A. Wilson, G.A. Cox, and S.M. Wilson Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity Mol. Cell. Neurosci. 39 2008 539 548
103. X. Wang, W. Stafford, M. Mazurkiewicz, M. Fryknas, S. Brjnic, X. Zhang, J. Gullbo, R. Larsson, E.S. Arner, P. D'Arcy, and S. Linder The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death Mol. Pharmacol. 85 2014 932 945
104. Y. Wang, J. Wang, J. Zhong, Y. Deng, Q. Xi, S. He, S. Yang, L. Jiang, M. Huang, C. Tang, and R. Liu Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer Med. Oncol. 32 2015 379
105. E. Weerapana, C. Wang, G.M. Simon, F. Richter, S. Khare, M.B. Dillon, D.A. Bachovchin, K. Mowen, D. Baker, and B.F. Cravatt Quantitative reactivity profiling predicts functional cysteines in proteomes Nature 468 2010 790 795
106. K. Wiberg, K. Carlson, A. Aleskog, R. Larsson, P. Nygren, and E. Lindhagen In vitro activity of bortezomib in cultures of patient tumour cells - potential utility in haematological malignancies Med. Oncol. 26 2009 193 201
107. S.M. Wilson, B. Bhattacharyya, R.A. Rachel, V. Coppola, L. Tessarollo, D.B. Householder, C.F. Fletcher, R.J. Miller, N.G. Copeland, and N.A. Jenkins Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease Nat. Genet. 32 2002 420 425
108. N. Wu, C. Liu, C. Bai, Y.P. Han, W.C. Cho, and Q. Li Over-Expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of beta-catenin Int. J. Mol. Sci. 14 2013 10749 10760
109. T. Yao, and R.E. Cohen A cryptic protease couples deubiquitination and degradation by the proteasome Nature 419 2002 403 407
110. T. Yao, L. Song, W. Xu, G.N. DeMartino, L. Florens, S.K. Swanson, M.P. Washburn, R.C. Conaway, J.W. Conaway, and R.E. Cohen Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1 Nat. Cell Biol. 8 2006 994 1002
111. B. Zhou, Y. Zuo, B. Li, H. Wang, H. Liu, X. Wang, X. Qiu, Y. Hu, S. Wen, J. Du, and X. Bu Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells Mol. Cancer Ther. 12 2013 1381 1392
112. P. Zwickl, A. Grziwa, G. Puhler, B. Dahlmann, F. Lottspeich, and W. Baumeister Primary structure of the Thermoplasma proteasome and its implications for the structure, function, and evolution of the multicatalytic proteinase Biochemistry 31 1992 964 972